Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    2,968 result(s) found. Displaying page 1 of 149.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-004529-17 Sponsor Protocol Number: YO39609 Start Date*: 2018-07-17
    Sponsor Name:F. Hoffman-La Roche Ltd
    Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED UNRESE...
    Medical condition: Locally advanced unresectable or Metastatic gastric or gastroesophageal junction cancer or esophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030151 Oesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001440-18 Sponsor Protocol Number: IACI2016 Start Date*: 2018-05-30
    Sponsor Name:university medical center utrecht
    Full Title: Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in cystic fibrosis patients and healthy controls
    Medical condition: cystic fibrosis and healthy subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004564-35 Sponsor Protocol Number: 205739 Start Date*: 2018-08-14
    Sponsor Name:GlaxoSmithKline Research and Development Ltd.
    Full Title: A Phase IIa Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study to Investigate the Clinical Efficacy, Safety, and Tolerability of Nemiralisib (GSK2269557) in Symptomatic COPD Particip...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)/chronic bronchitis and emphysema
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) NL (Prematurely Ended) ES (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-003008-30 Sponsor Protocol Number: 16/0730 Start Date*: 2020-07-01
    Sponsor Name:University College London
    Full Title: A double-blind, randomised, placebo-controlled single-site study of high dose simvastatin treatment for secondary progressive multiple sclerosis: impact on vascular perfusion and oxidative damage
    Medical condition: Multiple Sclerosis (Secondary Progressive)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10052785 Multiple sclerosis acute and progressive HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-003943-20 Sponsor Protocol Number: DX-2930-03 Start Date*: 2016-03-31
    Sponsor Name:Dyax Corp., an indirect, wholly-owned subsidiary of Shire plc.
    Full Title: HELP Study™: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX 2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
    Medical condition: Hereditary angioedema (HAE)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10075280 Hereditary angioedema attack LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004903-33 Sponsor Protocol Number: IBM4809 Start Date*: 2018-06-18
    Sponsor Name:Orphazyme A/S
    Full Title: Phase 2/3 Study of Arimoclomol in Inclusion Body Myositis (IBM) A Randomized, Double-blind, Placebo-Controlled Trial
    Medical condition: Sporadic Inclusion Body Myositis (sIBM)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10075052 Sporadic inclusion body myositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-000307-17 Sponsor Protocol Number: 69HCL16_0743 Start Date*: 2018-07-19
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Microcirculatory and Macrocirculatory Effects of Landiolol on Postoperative Atrial Fibrillation: a Randomized Study. MMELPOAF study.
    Medical condition: Postoperative Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002076-41 Sponsor Protocol Number: 0667 Start Date*: 2018-08-23
    Sponsor Name:University of Leicester
    Full Title: A RANDOMISED CONTROLLED TRIAL OF PRE-SURGERY SODIUM VALPROATE, FOR THE PREVENTION OF ORGAN INJURY IN CARDIAC SURGERY: Val-CARD
    Medical condition: Reduction of myocardial and kidney injury risk of post cardiac surgery by increasing the expression of genes that promote myocardial mitochondrial homeostasis via effects on chromatin histone deace...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10069339 Acute kidney injury PT
    20.1 100000004849 10057768 Post-cardiac injury syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-004527-67 Sponsor Protocol Number: DT-DP-DFU-CR-04 Start Date*: 2018-08-06
    Sponsor Name:DermaTools Biotech GmbH
    Full Title: A Randomised Dose Finding Study Comparing The Safety And Efficacy Of three blinded doses of Diperoxochloric Acid (DPOCl, DermaPro®) and A Standard Moist Wound Dressing In Patients With Non-Healing...
    Medical condition: Diabetic foot ulcer with mean diameter between 1.5 and 4 cm after débridement if indicated), Wound stage Wagner grade I or II, Armstrong stadium A or C (for Wagner-Armstrong-Classification), tr...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000754-35 Sponsor Protocol Number: R118528 Start Date*: 2017-07-18
    Sponsor Name:The University of Manchester
    Full Title: The effect of Denosumab on Pain and bone Marrow Lesions in symptomatic Knee Osteo-arthritis: A Randomised Double Blind Placebo controlled Clinical Trial
    Medical condition: Knee osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000019-26 Sponsor Protocol Number: D5670C00013 Start Date*: 2018-05-04
    Sponsor Name:MedImmune Limited, a wholly owned subsidiary of AstraZeneca
    Full Title: A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Subjects with Type 2 Diabetes Mellitus and Renal Impairment
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004745-70 Sponsor Protocol Number: 55438 Start Date*: 2018-11-06
    Sponsor Name:Academic Medical Center (AMC)
    Full Title: Efficacy of intranasal ketamine on acute suicidality, a double blind randomized placebo-controlled trial (Ketamine Trial Amsterdam, KETA)
    Medical condition: Acute suicidality, which is a rapid increase in suicidal ideation or behaviour from the patient's 'baseline' in the last 24 hours.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004348-39 Sponsor Protocol Number: 1708155 Start Date*: 2018-02-15
    Sponsor Name:CHU Saint-Etienne
    Full Title: Association between methotrexate erythrocyte polyglutamate concentration and clinical response in rheumatoid arthritis patients treated with subcutaneous injectable methotrexate
    Medical condition: rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10042952 Systemic rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000369-54 Sponsor Protocol Number: 60725 Start Date*: 2018-06-27
    Sponsor Name:University Medical Center Utrecht
    Full Title: Intra-arterial Lutetium-177- dotatate for treatment of patients with neuroendocrine tumor liver metastases
    Medical condition: Patients with neuro-endocrine tumors with liver metastases with an indication for treatment with lutetium-177-dotatate
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003028-59 Sponsor Protocol Number: NL62684.091.17 Start Date*: 2018-06-06
    Sponsor Name:Radboud University Medical Centre
    Full Title: Treatment with Recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with Anaplastic Thyroid Cancer: a proof of concept study
    Medical condition: Anaplastic Thyroid Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001387-12 Sponsor Protocol Number: CCLR325X2202 Start Date*: 2016-10-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, subject and investigator-blind, placebo-controlled study of CLR325 in chronic stable heart failure patients.
    Medical condition: Stable Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007558 Cardiac failure chronic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000188-33 Sponsor Protocol Number: MK-8616-146 Start Date*: 2017-10-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 4 Randomized, Active-Comparator Controlled Trial to Study the Efficacy and Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or ...
    Medical condition: Reversal of neuromuscular blockade
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10018061 General anesthesia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003426-89 Sponsor Protocol Number: E2020-J081-345 Start Date*: 2018-10-18
    Sponsor Name:Eisai Co., Ltd. (Japan)
    Full Title: A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disable...
    Medical condition: Down syndrome, regression symptoms and disabled activities of daily living
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000454-22 Sponsor Protocol Number: CCR4825 Start Date*: 2019-02-01
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: A translational phase II study of single agent Olaparib in the treatment of advanced oesophagogastric cancer
    Medical condition: Advanced Oesophago-gastric cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-003736-21 Sponsor Protocol Number: ACE-LY-110 Start Date*: 2017-06-07
    Sponsor Name:Acerta Pharma BV
    Full Title: A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects with Relapsed/Refractory B-cell Malignancies
    Medical condition: Part 1: De novo Diffuse large B-cell lymphoma (DLBCL), Transformed DLBCL and Richter syndrome (RS). Part 2: De novo Germinal center B-cell (GCB) DLBCL and De novo non-GCB DLBCL
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058728 Richter's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 11 03:23:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA